Losing by Winning at the Patent Office: Zytiga Case Illustrates How IPR Estoppel Could Reshape Patent Challenges and Delay Generic Launches

What does a recent case decided by the Federal Circuit Court mean for brand and generic manufacturer strategy in the future? Our Insight Brief reveals a subplot with potentially high stakes for payers, providers, and patients alike. Check out this brief to learn about loss-of-exclusivity-analysis.